Shilpa Medicare

Shares of Shilpa Medicare rose 6.23 per cent at Rs 917.20 per share on the BSE in Tuesday's intraday deals

Here is a list of stocks that will be in the limelight for November 19 session

Shilpa Medicare's shares surged as much as 8.45 per cent to hit an intraday high of Rs 894.50 per share

Shilpa Medicare share price surged after the company said that its arm, Shilpa Pharma Lifesciences, has received certificate of suitability (CEP) from EDQM for API, Desmopressin

Shares of Shilpa Medicare hit a new high of Rs 922, gaining 4% in Monday's intra-day trade after Antique Stock Broking initiate coverage on the stock with a BUY rating and a target price of Rs 1,300.

Northward surge in the stock price is attributed to the news that the company has received approval from the US Food and Drug Administration (USFDA) for its product, 'Bortezomib Injection NDA 212782

Shares of Shilpa Medicare were trading at Rs 733.15, up by nearly Rs 36, or 5.15 per cent on the BSE. In contrast, the 30-stock BSE Sensex was trading at 81,714 levels, up 0.77 per cent.

Shares of Shilpa Medicare soared up to 7.96 per cent at Rs 718.90 per share on the BSE in Wednesday's intraday deals

Shilpa Medicare hit a multi-year high of Rs 672.50, rallied 16% after the company's CDMO customer reported positive results from pivotal clinical trial & placed binding purchase order.

Across Asia, markets mirrored the losses seen in Wall Street, with Japan's Nikkei leading the decline with a drop of 1.22 per cent, followed by Korea's Kospi down nearly 1 per cent

Mindtree, Tata Metaliks, Deccan Health Care, Shree Ganesh Remedies and WS Industries are among eight companies that will release quarterly earnings today

The company has entered into a three-year Definitive Agreement with Dr. Reddy's for production-supply of the Sputnik V vaccine

Drug firm Shilpa Medicare on Monday said its arm has entered into a definitive agreement with Dr Reddy's Laboratories for manufacturing of Russian COVID-19 vaccine Sputnik V. "The company, via its wholly owned subsidiary Shilpa Biologicals Pvt Ltd (SBPL), has entered into a three year definitive agreement with Dr Reddy's Laboratories for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka," Shilpa Medicare said in a regulatory filing. The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of component 1 and 50 million of component 2), from the date of start of commercial production, the company added. Shilpa Medicare said Dr Reddy's will facilitate the transfer of the sputnik technology to SBPL. Under the agreement, SBPL will be responsible for manufacture of the vaccine, while Dr Reddy's is responsible for distribution/marketing of the vaccine in its ...

The company's shares jumped as much as 9.2% on India's National Stock Exchange following the news

The company believes that the warning letter will have minimum impact of disruption of supplies and the existing revenues from operations of this facility

The stock price has more than doubled in the past one month, from the level of Rs 260 on January 24, 2020

The company's Ebitda margin expanded by 1,550 basis points to 32.1 per cent in Q3FY20 from 16.6 per cent in Q3FY19

For Q1FY20, the company reported 55 per cent year-on-year (YoY) drop in its consolidated net profit at Rs 15 crore, due to lower sales

The stock surged 13% to Rs 434 on the BSE in morning trade after the company said it has received EIR from the US health regulator for it's both facilities located at Raichur, Karnataka.

The stock was 7% to Rs 488 on the BSE after the company received EIR from the USFDA for its formulation manufacturing facility in Telangana following the audit in November last year.